2604.01653 DOAC-BLEED-GFR v1: A Transparent Bleeding Risk Framework for DOAC Dosing in CKD Stage 3-4
DOAC-BLEED-GFR v1: We present a pre-validation composite scoring framework for ISTH major bleeding at 12 months in adult patients with non-valvular atrial fibrillation or VTE on DOAC therapy with eGFR 15-59 mL/min/1.73m2.